Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694336 | 0.86 | MAPT (0.43) | MAPTGAAALDH1A1KDM4E | |
| SCHEMBL1414747 | 0.85 | ABL1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL7864090 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL2874812 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL7863952 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL5543069 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL10769826 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL2059888 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL222543 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL220260 | 0.83 | ABL1 (0.47) | MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101591530-B | Fluorescent probe for detecting glutathione reductase and bioactive sulfhydryl compound, and synthetic method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2013-01-23 | — | — | CN | claimed |
| CN-101525497-B | pyrazoline pyridino-benzo coumarin fluorescent dye derivative and synthesis method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2012-07-04 | — | — | CN | claimed |
| CN-101368003-B | pyrazoline pyridino-coumarin fluorescent dye derivative and synthesis method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2011-09-14 | — | — | CN | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| CN-101591530-A | Fluorescent probe for detecting glutathione reductase and bioactive sulfhydryl compound, and synthetic method and application thereof | CHINESE ACAD TECH INST PHYSICS (CN) | 2009-12-02 | — | — | CN | claimed |
| CN-101525497-A | Pyrazoline pyridino-benzo coumarin fluorescent dye derivative and synthesis method and application thereof | CHINESE ACAD TECH INST PHYSICS (CN) | 2009-09-09 | — | — | CN | claimed |
| EP-1781617-A4 | ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| CN-101368003-A | Pyrazoline pyridino-coumarin fluorescent dye derivative and synthesis method and application thereof | CHINESE ACAD TECH INST PHYSICS (CN) | 2009-02-18 | — | — | CN | claimed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | claimed |
| EP-1076649-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 2001-02-21 | — | — | EP | claimed |
| US-6127381-A | A MELANOCORTIN RECEPTOR LIGAND FOR REGULATING FOOD INTAKE AND BODY WEIGHT, REGULATING CYTOKINE ACTIVITY, ANTI-INFLAMMATORY ACTIVITY | LION BIOSCIENCE AG (DE) | 2000-10-03 | — | — | US | claimed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1999055679-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0032856-B1 | 2,3-DIHYDROIMIDAZO (1,2-B) PYRIDAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SYNTHELABO (FR) | 1983-02-09 | — | — | EP | claimed |
| US-4353903-A | 2,3-Dihydro-imidazo[1,2-b]pyridazine derivatives, their preparation and use in treatment of depression | SYNTHELABO (FR) | 1982-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAPT 173/4885GAA 11/4885ALDH1A1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.